Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITUX 4
2024-514886-21-00Phase 4Authorised
- Sponsor
- Rouen University Hospital
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Concomitant systemic corticosteroid requirement prior to randomization. Planned start Aug 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on 2024-514886-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514886-21-00.